NVS Quote, Financials, Valuation and Earnings

GSK PLC has a net margin of 20.79% compared to Novartis AG's net margin of 5.1%. Novartis AG's return on equity of 27.64% beat GSK PLC's return on equity of 19.22%.

Novartis AG has a consensus price target of $109.37, signalling downside risk potential of -2.54%. On the other hand GSK PLC has an analysts' consensus of $43.42 which suggests that it could grow by 7.88%. Given that GSK PLC has higher upside potential than Novartis AG, analysts believe GSK PLC is more attractive than Novartis AG.

Novartis AG has a beta of 0.540, which suggesting that the stock is 45.99% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.601, suggesting its less volatile than the S&P 500 by 39.914%.

Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.45%. GSK PLC offers a yield of 3.86% to investors and pays a quarterly dividend of $0.40 per share. Novartis AG pays 63.85% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than GSK PLC quarterly revenues of $10.4B. Novartis AG's net income of $2.8B is higher than GSK PLC's net income of $530.1M. Notably, Novartis AG's price-to-earnings ratio is 19.09x while GSK PLC's PE ratio is 25.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.41x versus 2.07x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 20.79% compared to Novartis AG's net margin of 32.59%. Novartis AG's return on equity of 27.64% beat Eli Lilly and's return on equity of 80.24%.

Novartis AG has a consensus price target of $109.37, signalling downside risk potential of -2.54%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 22.05%. Given that Eli Lilly and has higher upside potential than Novartis AG, analysts believe Eli Lilly and is more attractive than Novartis AG.

Novartis AG has a beta of 0.540, which suggesting that the stock is 45.99% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.45%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Novartis AG pays 63.85% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Eli Lilly and quarterly revenues of $13.5B. Novartis AG's net income of $2.8B is lower than Eli Lilly and's net income of $4.4B. Notably, Novartis AG's price-to-earnings ratio is 19.09x while Eli Lilly and's PE ratio is 70.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.41x versus 16.55x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 20.79% compared to Novartis AG's net margin of 2.31%. Novartis AG's return on equity of 27.64% beat Pfizer's return on equity of 8.91%.

Novartis AG has a consensus price target of $109.37, signalling downside risk potential of -2.54%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 20.22%. Given that Pfizer has higher upside potential than Novartis AG, analysts believe Pfizer is more attractive than Novartis AG.

Novartis AG has a beta of 0.540, which suggesting that the stock is 45.99% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.45%. Pfizer offers a yield of 6.49% to investors and pays a quarterly dividend of $0.43 per share. Novartis AG pays 63.85% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Novartis AG quarterly revenues are $13.6B, which are smaller than Pfizer quarterly revenues of $17.8B. Novartis AG's net income of $2.8B is higher than Pfizer's net income of $410M. Notably, Novartis AG's price-to-earnings ratio is 19.09x while Pfizer's PE ratio is 18.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.41x versus 2.33x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 20.79% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 27.64% beat Roche Holding AG's return on equity of 23.8%.

Novartis AG has a consensus price target of $109.37, signalling downside risk potential of -2.54%. On the other hand Roche Holding AG has an analysts' consensus of $46.29 which suggests that it could grow by 4.63%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.540, which suggesting that the stock is 45.99% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.628%.

Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.45%. Roche Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $1.35 per share. Novartis AG pays 63.85% of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $2.8B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 19.09x while Roche Holding AG's PE ratio is 30.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.41x versus 4.05x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.